查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949636

蛋白質工程市場－全球產業規模、佔有率、趨勢、機會及預測（依產品類型、技術、最終用戶、地區及競爭格局分類，2021-2031年）

Protein Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球蛋白質工程市場預計將從 2025 年的 31.4 億美元大幅成長至 2031 年的 64.2 億美元，複合年成長率達 12.66%。

該領域專注於系統性地改造蛋白質結構，以創造具有最佳化特性（例如觸媒活性、特異性和穩定性）的新型分子。推動此領域發展的主要因素是：對重組療法和單株抗體的需求不斷成長，這些療法和抗體可用於治療自體免疫疾病和癌症等慢性疾病；以及利用工程酶進行永續生物製造的趨勢。歐洲製藥工業協會聯合會 (EFPIA) 的報告也體現了這種對創新的堅定承諾，該報告指出，到 2024 年，歐洲以研發為基礎的製藥業將在研發方面投入約 550 億歐元。

市場概覽
預測期 2027-2031
市場規模：2025年 31.4億美元
市場規模：2031年 64.2億美元
複合年成長率：2026-2031年 12.66%
成長最快的細分市場 學術機構
最大的市場 北美洲

儘管存在這些積極跡象，但市場仍面臨著與新型生物製藥開發固有的高技術複雜性和營運成本相關的重大障礙。確保蛋白質穩定性並避免免疫抗原性需要複雜的製程，這會延長開發週期並增加資金需求。此外，產品核可中嚴格且不斷變化的監管環境也可能導致額外的延誤，顯著增加中小型生物技術公司的進入門檻，並可能減緩市場整體成長速度。

市場促進因素

機器學習和人工智慧的融合正在以前所未有的精度和速度實現從頭設計，從而變革蛋白質工程領域。這些計算工具使研究人員能夠在物理合成之前預測複雜的蛋白質結構並最佳化其功能特性，例如穩定性和結合親和性。透過減少對傳統人工篩檢技術的依賴，這項技術加速了針對特定生物標的設計的分子的建構。這種協同效應的商業性前景正在推動大量投資；例如，Xaira Therapeutics 於 2024 年 4 月宣布已獲得超過 10 億美元的資金籌措，用於建立一個以人工智慧為中心的平台，致力於重新設計藥物發現流程。

同時，全球對用於治療慢性疾病的重組蛋白和單株抗體的需求不斷成長，正推動著生產能力的顯著擴張。隨著代謝性疾病和自體免疫疾病的日益增多，製藥開發商正致力於大規模生產工程化生物製藥，這些製劑相比小分子藥物具有更高的特異性。這一趨勢體現在為保障供應鏈而進行的大規模基礎設施投資。例如，諾和諾德在2024年6月宣布，將投資41億美元在北卡羅來納州克萊頓新建一座注射生產設施。同樣，Astra Zeneca於2024年宣布，將投資3億美元新建一座專注於下一代生物製劑和細胞療法的生產設施，以確保未來的產能。

市場挑戰

全球蛋白質工程市場的發展受到高昂營運成本和技術複雜性的嚴重限制，而這些成本和技術複雜性是開發新型生物製藥的關鍵所在。實現必要的蛋白質穩定性並防止免疫抗原性需要專門的基礎設施和廣泛的研究，這導致開發週期長、資本支出巨大。這種資源密集型環境設定了很高的進入門檻，使得中小型生物技術公司難以有效參與競爭，也難以透過嚴格而漫長的監管核准流程來維持業務。

這些資金限制直接阻礙了市場擴張，因為它們限制了成功商業化的創新計劃數量。近期投資趨勢表明，新興產業參與者的資金籌措大幅縮減，這凸顯了這種壓力的嚴重性。根據生技創新組織（BIO）的數據顯示，生技Start-Ups的資金籌措從2025年第一季的26億美元驟降至第二季的僅9億美元。Start-Ups可用資金的減少限制了該產業推出新型重組蛋白療法的能力，從而減緩了整個產業的成長速度。

市場趨勢

與傳統的單株抗體開發模式不同，製藥業正日益專注於開發多特異性和雙特異性抗體。為了更精準地治療異質性固態腫瘤，研發人員擴大利用蛋白質工程技術來建構複雜的治療模式，例如能夠同時結合兩種或多種不同抗原的T細胞銜接器。這種朝向多標靶架構的轉變，能夠引導免疫效應細胞標靶腫瘤部位，進而增強腫瘤治療效果，而生物製藥則不具備這種能力。這些專業平台的高價值也反映在策略收購中。例如，默克公司於2024年1月宣布，將以約6.8億美元的以金額為準收購Harpoon Therapeutics，以整合該公司的三特異性抗體技術。

同時，市場正顯著多元化發展，拓展至環境和工業酵素應用領域，使其重要性超越了醫藥應用。蛋白質工程在循環經濟中正變得至關重要，尤其是在設計高性能酵素以分解和回收合成纖維和塑膠方面。這種方法將重點從合成轉移到材料分解和廢棄物化利用，從而支持包裝和消費品行業的永續性目標。這項產業轉型得到了大規模資本計劃的推動。例如，Calbios於2024年4月啟動了全球首個工業PET生物回收工廠，預計投資金額達2.3億歐元，凸顯了工程酶在環境管理領域的商業性潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球蛋白質工程市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（胰島素、單株抗體、凝血因子{血液因子+組織型胞漿素原}、疫苗、生長因子{荷爾蒙+細胞激素}、其他產品類型）
    • 按技術分類（非理性蛋白質設計與理性蛋白質設計）
    • 以最終用戶（製藥和生物技術公司、學術機構、合約研究組織 {CRO}）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美蛋白質工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲蛋白質工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區蛋白質工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲蛋白質工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲蛋白質工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球蛋白質工程市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies Inc.
  • Amgen Inc.
  • Bruker Corporation
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16973

The Global Protein Engineering Market is projected to expand significantly, rising from a valuation of USD 3.14 Billion in 2025 to USD 6.42 Billion by 2031, reflecting a compound annual growth rate of 12.66%. This field centers on the systematic modification of protein structures to create novel molecules with optimized traits, such as enhanced catalytic activity, specificity, or stability. Growth is largely fueled by the rising need for recombinant therapeutics and monoclonal antibodies to manage chronic diseases like autoimmune disorders and cancer, alongside a shift toward sustainable biomanufacturing using engineered enzymes. This strong commitment to innovation is evidenced by the European Federation of Pharmaceutical Industries and Associations, which reported that the research-based pharmaceutical sector in Europe invested approximately €55 billion in R&D during 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.14 Billion
Market Size 2031USD 6.42 Billion
CAGR 2026-203112.66%
Fastest Growing SegmentAcademic Institutions
Largest MarketNorth America

Despite these positive indicators, the market encounters substantial obstacles related to the high technical complexity and operational costs inherent in developing new biologics. Ensuring protein stability while avoiding immunogenicity necessitates intricate processes that prolong development schedules and increase capital requirements. Furthermore, navigating strict and changing regulatory landscapes for product approval poses additional delays, creating significant barriers to entry for smaller biotechnology firms and potentially retarding the overall pace of market growth.

Market Driver

The incorporation of machine learning and artificial intelligence is transforming the protein engineering sector by facilitating de novo design with unprecedented accuracy and speed. These computational tools enable researchers to forecast complex protein structures and refine functional characteristics, such as stability and binding affinity, prior to physical synthesis. By diminishing the reliance on conventional, labor-heavy screening techniques, this technology expedites the creation of molecules designed for specific biological targets. The commercial promise of this synergy is driving significant investment; for instance, Xaira Therapeutics announced in April 2024 that it had secured over $1 billion in committed capital to establish an AI-centric platform dedicated to redesigning drug discovery.

Concurrently, the rising global requirement for recombinant proteins and monoclonal antibodies to treat chronic conditions is driving a major expansion in manufacturing capabilities. As metabolic and autoimmune diseases become more prevalent, pharmaceutical developers are focusing on the scalable production of engineered biologics that provide better specificity compared to small-molecule drugs. This trend is highlighted by substantial infrastructure investments to secure supply chains, such as Novo Nordisk's June 2024 announcement of a $4.1 billion investment in a new injectable treatment facility in Clayton, North Carolina. Similarly, in 2024, AstraZeneca committed $300 million to a new site dedicated to next-generation biologics and cell therapy to ensure adequate future capacity.

Market Challenge

The Global Protein Engineering Market is significantly hindered by the substantial operational expenses and technical intricacies involved in creating novel biologics. Achieving necessary protein stability and preventing immunogenicity demands specialized infrastructure and extensive research, leading to prolonged development timelines and steep capital expenditures. This resource-intensive environment establishes a formidable barrier to entry, making it challenging for smaller biotechnology companies to compete effectively or maintain operations throughout the rigorous and lengthy regulatory approval process.

These financial constraints directly impede market expansion by limiting the volume of innovative projects that successfully reach commercialization. The severity of this pressure is illustrated by recent trends in investment, which indicate a sharp contraction in funding available for emerging industry players. According to the Biotechnology Innovation Organization, biotech startup funding fell precipitously from $2.6 billion in the first quarter of 2025 to just $900 million in the second quarter. This reduction in accessible capital for startups restricts the industry's ability to introduce new engineered protein therapies, thereby slowing the overall growth trajectory of the sector.

Market Trends

There is a growing industry focus on engineering multispecific and bispecific antibodies, a trend that distinguishes the current market from standard monoclonal antibody development. Developers are increasingly leveraging protein engineering to construct complex modalities, such as T-cell engagers, capable of binding simultaneously to two or more distinct antigens to improve therapeutic precision against heterogeneous solid tumors. This move toward multi-targeting architectures enhances oncological efficacy by directing immune effector cells straight to tumor sites, a function not found in traditional biologics. The high value placed on these specialized platforms is reflected in strategic acquisitions, such as Merck's January 2024 agreement to acquire Harpoon Therapeutics for an equity value of approximately $680 million to incorporate its trispecific antibody technologies.

In parallel, the market is diversifying significantly into environmental and industrial enzyme applications, extending the sector's relevance beyond pharmaceutical uses. Protein engineering is becoming essential for the circular economy, particularly in designing high-performance enzymes that depolymerize synthetic fibers and plastics for recycling. This approach shifts the focus from synthesis to material degradation and waste valorization, supporting sustainability objectives in packaging and consumer goods. This industrial shift is backed by substantial capital projects, such as Carbios' advancement in April 2024 of the world's first industrial PET biorecycling plant, representing an estimated investment of €230 million and highlighting the commercial potential of engineered enzymes in environmental management.

Key Market Players

  • Agilent Technologies Inc.
  • Amgen Inc.
  • Bruker Corporation
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

Report Scope

In this report, the Global Protein Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Engineering Market, By Product Type

  • Insulin
  • Monoclonal Antibodies
  • Coagulation Factors {Blood Factors + Tissue Plasminogen}
  • Vaccines
  • Growth Factors {Hormones + Cytokine}
  • Other Product Types

Protein Engineering Market, By Technology

  • Irrational Protein Design
  • Rational Protein Design

Protein Engineering Market, By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions
  • Contract Research Organizations {CROs}

Protein Engineering Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Engineering Market.

Available Customizations:

Global Protein Engineering Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Engineering Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors {Blood Factors + Tissue Plasminogen}, Vaccines, Growth Factors {Hormones + Cytokine}, and Other Product Types)
    • 5.2.2. By Technology (Irrational Protein Design and Rational Protein Design)
    • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations {CROs})
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Protein Engineering Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Protein Engineering Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Protein Engineering Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Protein Engineering Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User

7. Europe Protein Engineering Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Protein Engineering Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. France Protein Engineering Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Protein Engineering Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Protein Engineering Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Protein Engineering Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. Asia Pacific Protein Engineering Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Protein Engineering Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. India Protein Engineering Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Protein Engineering Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Protein Engineering Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Protein Engineering Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End User

9. Middle East & Africa Protein Engineering Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Protein Engineering Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Protein Engineering Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Protein Engineering Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. South America Protein Engineering Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Protein Engineering Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Protein Engineering Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Protein Engineering Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Protein Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Bruker Corporation
  • 15.4. Bio-Rad Laboratories Inc.
  • 15.5. Eli Lilly and Company
  • 15.6. Merck KGaA
  • 15.7. Novo Nordisk AS
  • 15.8. PerkinElmer Inc.
  • 15.9. Thermo Fisher Scientific Inc.
  • 15.10. Waters Corporation

16. Strategic Recommendations

17. About Us & Disclaimer